Table 2.
Immunoblot Expression Levels in DMAT Treated PC3-LN4 Tumors1
| Protein Analyzed | TBG-DMAT 100 μg/kg2 N=4 |
TBG-DMAT 20 μg/kg3 N=3 |
Naked DMAT 500 μg/kg4 N=2 |
Vehicle5 N=4 |
|---|---|---|---|---|
| CK2α | 1.01 ± 0.05 (p = 0.997) | 0.59 ± 0.08 (p = 0.004) | 1.03 ± 0.17 (p = 0.989) | 1 |
| CK2α′ | 0.92 ± 0.07 (p = 0.653) | 0.44 ± 0.07 (p = 0.0004) | 0.91 ± 0.13 (p = 0.697) | 1 |
| CK2β | 0.92 ± 0.08 (p = 0.944) | 1.40 ± 0.84 (p = 0.167) | 0.89 ± 0.005 (p = 0.930) | 1 |
| NF-κB p65 | 0.71 ± 0.10 (p = 0.074) | 0.59 ± 0.10 (p = 0.023) | 0.87 ± 0.17 (p = 0.712) | 1 |
| NF-κB p65 p-Ser529 | 0.82 ± 0.06 (p = 0.215) | 1.02 ± 0.09 (p = 0.997) | 1.41 ± 0.19 (p = 0.017) | 1 |
1
All values normalized to actin expression and expressed relative to vehicle control treatment as mean ± SE. p values are listed underneath the corresponding protein expression value for comparison with vehicle control.
2
Administered once daily, first 2 doses iv, last 6 doses ip, all doses at 100 μg/kg.
3
Administered once daily, first 2 doses iv at 100 μg/kg, last 4 doses ip at 20 μg/kg.
4
Administered once daily, all 6 doses ip at 500 μg/kg.
5
Administered once daily, all 8 doses ip.